108results about How to "Good drug release" patented technology

The invention relates to a mesoporous nano silicon ball compound targeting drug delivery system as well as a preparation method and application thereof. The preparation method of the mesoporous nano silicon ball compound targeting drug delivery system comprises the following steps: 1) preparing amino-functionalized drug loading mesoporous silicon dioxide microspheres; 2) preparing hyaluronic acid-hydrosulphonyl polypeptide-adriamycin (HA-RGD-DOX); 3) preparing mesoporous microsphere-hyaluronic acid-hydrosulphonyl polypeptide-adriamycin--paclitaxel (MSNs-HA-RGD-DOX_PTX); and 4) preparing fluorescent marker modified mesoporous microsphere-hyaluronic acid-hydrosulphonyl polypeptide-adriamycin--paclitaxel compound (MSNs-HA-RGD-DOX-PTX). The mesoporous nano silicon ball compound targeting drug delivery system has the beneficial effects that firstly multi-targeting synergistic drug delivery is realized, multiple tumour cells and tissues can be killed, and reversal drug resistance is good; secondly, blood stability is excellent; thirdly, invisibility, drug release degree and controlled release properties are good; fourthly, in vivo tracing function is good; and fifthly, the mesoporous nano silicon ball compound targeting drug delivery system has good general applicability.

The invention discloses an improved-performance tablet which comprises an active component A1, a hydrophilic diluent B1 and a meltable solid dispersion and/or a solid coating C1, wherein the diluent B1 and/or the active component A1 are/is bonded and bridged by the solidified melt of the meltable solid dispersion and/or solid coating C1; and/or the tablet comprises a hydrophilic diluent B2 and a meltable solid dispersion containing an active component A2 and/or a solid coating C2, wherein the diluent B2 is bonded and bridged by the solidified melt of the meltable solid dispersion and/or solid coating C2. The invention also discloses a preparation method of the tablet. The tablet has stronger mechanical performance and/or better weather resistance and/or better hydrophilcity or better disintegration property or better medicine dissolubility and higher porosity.

The invention discloses a suppository composition with improved performance. The suppository composition comprises an aliphatic suppository substrate, mono-capryl-based glycerin, mono-lauroyl-based glycerin, polyoxyethylene, a suppository substrate of which the molecular structure contains polyethylene glycol and alkyl having 8 to 24 carbon atoms and a suppository medicament. The suppository composition has the advantages of improving production repeatability and retention value otherness, enhancing the function of a cavity administration retention substrate, improving stability, namely, changing melting performance, decreasing medicament releasing rate and solving or relieving problems such as scumming and the like, improving medicament releasing performance, increasing liquefaction or gelling speed and achieving stronger salt resistance and acid resistance and higher biocompatibility and the like.

The invention discloses an amphiphilic camptothecin polymer prodrug taking phenylboronic acid ester as a connecting unit and a co-delivery micelle system thereof. A polyethylene glycol-polyglutamate camptothecin two-block polymer (mPEG-BC-PGluCPT) is synthesized by taking catechol phenylborate (BC) as a connecting unit, and then a doxorubicin loaded micelle (mPEG-BC@PGluCPT.Dox) of the polymer isconstructed. Aiming at the poor water solubility of camptothecin, a polymer prodrug using camptothecin as a hydrophobic end by modifying 20 sites of hydroxyl groups of camptothecin is synthesized, which can effectively promote the assembly of the two-block polymer into a micelle. The solubility of camptothecin is improved, the stability of a camptothecin lactone ring is increased, and the curativeeffect and bioavailability are improved in order to overcome limitations of clinical treatment of camptothecin. The amphiphilic camptothecin polymer prodrug prepared by the method provided by the invention can be used for constructing a nano drug common delivery system, and has good drug release property, strong cell inhibition rate and good cell phagocytosis.

The invention provides a curcumin-carried pH-response color-changing antibacterial fiber and a preparation method thereof. The preparation method comprises the following steps: step 1, drying and dewatering polyacrylonitrile powder, and filtering for separating by utilizing a screen mesh; step 2, mixing curcumin, the polyacrylonitrile powder obtained in the step 1 and a solvent, wherein the mass concentration of the polyacrylonitrile is 18-22%, and the consumption of the curcumin is 0.5-5% of the polyacrylonitrile powder in dry weight; and step 3, stirring a mixed liquid obtained in the step 2 to puff and dissolve polyacrylonitrile to obtain a spinning solution, performing deaeration on the spinning solution, performing wet spinning to obtain a nascent fiber, performing drying densification on the obtained nascent fiber, and performing heat setting treatment, so as to obtain the curcumin-carried pH-response color-changing antibacterial fiber. According to the curcumin-carried pH-response color-changing antibacterial fiber and the preparation method thereof, the fiber is colored uniformly, the color fastness is excellent, and the fiber has the weaving mechanical property and the pH-response color-changing performance; the spinning temperature is low, and the medicine activity of curcumin can be still retained, so that the fiber has the anti-bacterial function.

The invention discloses a diblock polymer with benzeneboronic acid ester as the connecting unit. Benzeneboronic acid catechol ester (BC) is adopted as the connecting unit to synthesize PEG-BC-PBLG diblock polymer so as to construct doxorubicin loaded micelle (PEG-BC@PBLG.Dox). The invention also discloses a preparation method of the diblock polymer, and the method includes: (1) preparing the dopa derivative PEG-3, 4-DA of PEG-NH2; (2) subjecting PEG-3, 4-DA and 3-aminophenylboronic acid to dehydration condensation so as to synthesize the benzeneboronic acid ester derivative PEG-BC of PEG; and (3) using PEG-BC to perform ring opening on 5-benzyl ester-L-glutamic acid-N-carboxyanhydride (BLG-NCA), thus obtaining the diblock polymer PEG-BC-PBLG with benzeneboronic acid ester as the connecting unit. The diblock polymer prepared by the method provided by the invention can be used for construction of a nano-micelle, and has the advantages of good drug release, low cytotoxicity and good cell phagocytosis.

The invention discloses a tablet with improved combination properties. The tablet comprises an active constituent, a water soluble crystalline granular or powdered diluent, a melting adhesive, a melting mechanical property improver and/or does not comprise a pharmaceutically acceptable additive, wherein the diluent and/or the active constituent are/is adhered and bridged by the cured smelt of theadhesive and the mechanical property improver; the ratio of the mechanical property improver to the summation of the adhesive and the mechanical property improver is 0.25-0.70, and the ratio of the diluent to the summation of the adhesive, the mechanical property improver and the diluent is 0.40-0.93; the content of the diluent is not lower than 25 percent; and the contents of the adhesive and the mechanical property improver are not lower than 5 percent. The invention also discloses a preparation method of the tablet. The tablet has the advantages of stronger mechanical property, better weather resistance, better hydrophilcity, higher porosity and better disintegration property.

Disclosed are a receptor-mediated quantum dot tracing targeted drug delivery system, a preparation method thereof and application. The targeted drug delivery system comprises polyethylene glycol, hyaluronic acid, quantum dots and melphalan complex which are abbreviated as PEG-HA-QDs-MEL. The PEG is connected with HA amide in a dewatered and condensed manner, the water-soluble CdTe/CdS quantum dots are connected into the HA, and finally, the PEG, the HA and the QDs are prepared with the MEL complex to obtain the targeted drug delivery system. The component content of the PEG-HA-QDs-MEL includes, by weight, 30-100 parts of the MEL, 600-1500 parts of the PEG, 200-500 parts of the HA, 5-50 parts of the CdTe/CdS quantum dots, 20-50 parts of DCC (dicyclohexylcarbodiimide), 1-10 parts of DMAP (dimethylamino-pyridine), 100-500 parts of succinic anhydride, 20-50 parts of NHS, 20-50 parts of EDC (carbodiimide) and 10-100 parts of sodium bisulfite. The targeted drug delivery system is applied to preparing antitumor drugs.

The invention discloses a beneficiation method for copper-lead sulphide ore, and belongs to the technical field of beneficiation. The method comprises raw ore grinding, copper-lead mixing flotation and copper-lead separation. Copper-lead mixing flotation comprises primary copper-lead roughing, tertiary copper-lead fine selecting and secondary copper-lead scavenging. Copper-lead separation comprises primary copper roughing, tertiary copper fine selecting and secondary copper scavenging. Lime, calcium hypochlorite, zinc sulfate, sodium sulfite, sodium sulphide, dimethyl dicarbonate, sodium pyrophosphate, sodium citrate, ethionine ester, ethyl thio carbamate, sodium n-butylxanthate, aniline aerofloat, diphenyl amino phosphorodithioic acid and sodium carbonate are added in the copper-lead roughing and copper-lead scavenging processes. Lime, water glass, sodium phosphate starch, carboxymethyl starch, phthalic acid, thiosalicylic acid, ethionine ester and sodium ethylxanthate are added in the copper roughing and copper scavenging processes. The beneficiation method solves the problem that in the process of beneficiation of the copper-lead sulphide ore through a traditional flotation method, the copper and lead recycling rate is low.

The invention relates to a temperature-sensitive hydrogel containing exendin-4, comprising exendin-4 as an effective ingredient and an amphiphilic copolymer as a medicine slow release carrier, wherein, the amphiphilic copolymer comprises polyester and polyethylene glycol, preferred PLGA-PEG-PLGA. The temperature-sensitive hydrogel is a liquid at room temperature, and is a solid water insoluble gel at the temperature of 37 DEG C, can be used for treating diabetes, and has good drug release property, environmental protection, little irritation, convenient application, and obvious effect. Compared with preparations with a large dose of exendin-4, the hydrogel disclosed herein has the advantages of in vivo formation of gel, easy operation, and continuous release property, and improves bioavailability, reduces administration times, and enhances patient compliance.

The invention discloses a slow-release drug carrier with improved performance. The drug carrier contains (a) an aliphatic additive in vivo-in vitro fusing points of which is higher than 37 DEG C, (b) low-viscosity water-soluble nonirritant additive particles, (c) a water-swelling and water-insoluble acidic (or alkaline) polymer, (d) an alkaline (or acidic) surfactant, and (e) a medicament. The drug carrier has the advantages of better drug release character, higher 'salt poisoning' resistance effect, lower mucosal irritation, better biocompatibility and better drug release uniformity, thus better relieving or solving 'terminal release' problem and avoiding medication safety problems such as burst drug release or dose dumping and the like.

The invention discloses a two-block double-sensitive camptothecin polymer prodrug taking benzeneboronic ester as a connecting unit and a preparation method of the two-block double-sensitive camptothecin polymer prodrug. The two-block double-sensitive camptothecin polymer prodrug takes benzeneboronic catechol ester (BC) as the connecting unit, polyethylene glycol-polyglutamate disulfide ethanol camptothecin two-block polymer (PEG-BC-PGlu-ss-CPT) is synthesized, thereby constructing a self-assembly prodrug nano micelle, namely PEG-BC@PGlu-ss-CPT; PEG-BC is taken as a macroinitiator an initiatorto perform an open-loop polymerization reaction on a reduction-sensitive camptothecin monomer to obtain the two-block double-sensitive camptothecin polymer prodrug PEG-BC-PGlu-ss-CPT taking the benzeneboronic ester as the connecting unit. The prepared prodrug micelle can improve the solubility of camptothecin and improve the stability of a camptothecin lactone ring so as to overcome the limitationof camptothecin clinical treatment, and the prodrug micelle has a good drug release property and dual sensitive properties of acid sensitivity and reduction sensitivity.

The invention provides multi-layer grafted silicon dioxide nanoparticles, layer-by-layer molecular imprints are used for covalently assembling amino-terminated silicon dioxide and aldehyde-terminated silicon dioxide, and the imprint process is repeated according to needs until the needed silicon dioxide layer number is reached. The invention further provides high-viscoelasticity Pickering emulsion prepared from the nanoparticles. The fractal silicon dioxide is synthesized through the layer-by layer molecular imprint technology and can be used for preparing the high-viscoelasticity Pickering emulsion, the obtained emulsion is high in viscoelasticity, high in stability and good in drug release degree. In addition, the used raw material silicon dioxide particles are low in price and easy to obtain, and the high-viscoelasticity Pickering emulsion is low in production cost and good in biocompatibility and therefore not limited when applied to the fields of food, cosmetics and medicine. The layer-by layer molecular imprint technology is easy to operate and industrialize.

The invention relates to a new drug delivery system of gynaecologic panchrest plaster. The system consists of 0.16-0.36kg of dimethyl sulfone, 0.13-0.33kg of eucalyptus oil, 5.68-7.68kg of rubber, 0.6-1.5kg of vaseline, 0.30-1.00kg of lanolin, 7.8-9.8kg of zinc oxide, 0.28-0.48kg of liquid paraffin, 5.0-7.0kg of rosin and 5.33kg of traditional Chinese medicine extract. With the drug delivery system of the above prescription for drug loading, the gynaecologic panchrest plaster produced has consistent color, smooth cut opening and good drug delivery effect, with the incidence rate of skin irritation and anaphylaxis reduced to less than 0.8%.

The invention discloses a fusion protein, the amino acid sequence of which contains an iRGD peptide sequence shown as SEQ ID No:1 and a molecular chaperone GroEL sequence shown as SEQ ID No:2. The invention further discloses an encoding gene of the fusion protein, the sequence of which is a nucleotide sequence capable of encoding the fusion protein. The invention further discloses a preparation method of the fusion protein. The preparation method comprises the following step of expressing the encoding gene in a bacterial strain to obtain the fusion protein. A method of preparing a pharmaceutical composition comprises the following steps of contacting the pharmaceutical compound with the fusion protein disclosed by the invention to obtain a contacted material in the presence of a solvent. The invention further discloses the pharmaceutical composition prepared by the method of preparing the pharmaceutical composition. The fusion protein provided by the invention can stably load a hydrophobic drug, and is high in drug-carrying efficiency and good in drug release effect. The pharmaceutical composition prepared by the fusion protein provided by the invention has the advantages of good biocompatibility and good drug release effect.

The invention provides a rapamycin slow-release dosage form as well as a preparation method, a rapamycin slow-release injection and application, which relate to the technical field of medicines. The rapamycin slow-release dosage form comprises rapamycin and a slow-release material in a mass ratio of 1: (10 to 50). The rapamycin slow-release dosage form is high in drug content, capable of realizinga slow-release and controlled-release effect of a drug, and capable of effectively alleviating and treating osteoarthritis. The preparation method of the rapamycin slow-release dosage form provided by the invention is simple to operate, and the prepared rapamycin slow-release dosage form is good in stability, long in retention time in a human body, high in bioavailability, and favorable for the popularization and application of industrialized production. The rapamycin slow-release injection can be directly injected without using an organic solvent, can reduce the adverse reaction and safety accidents caused by the organic solvent, is long in retention time in the human body, does not need to be repeatedly injected for multiple times, can reduce the cost of administrating the drug for multiple times, and can alleviate the pain of a patient and the irritation.

The invention relates to a bioactive glass hydrocolloid dressing for promoting wound healing and a preparation method and application thereof. The hydrocolloid dressing consists of a backing layer, a drug-containing colloid layer and an anti-sticking layer; the drug-containing colloid layer consists of a thermoplastic elastomer, tackifying resin, a plasticizer, an antioxidant, a water-absorbent colloid, acidic particles, bioactive glass and sanggenone G; and the bioactive glass consists of Na2O, CaO, P2O5 and SiO2, and the particle size is 40-60 [mu]m. The drug-containing bioactive glass hydrocolloid dressing of the invention has excellent adhesion performance, drug release performance and high water absorption capacity; the function of promoting wound healing and wound repair of the hydrocolloid dressing can be greatly enhanced; and the dressing is convenient to use, high in stability, low in irritation, and is especially suitable for treating chronic ulcerative wounds such as diabetic ulcers, diabetic feet and bedsores.

The invention discloses a medicament carrier for releasing a medicament in a sustained-release way. The medicament carrier comprises (a) an aliphatic additive of which the melting points in vivo and vitro are higher than 37 DEG C, (b) water-soluble, low-viscosity and non-irritating additive particles, (c) a water-swellable and water-insoluble acidic (or alkaline) polymer, (d) an alkaline (or acidic) substance, (e) a water-soluble surfactant and (f) a medicament. The medicament carrier has high medicament release properties, a good anti-salt poisoning effect and high medicament release uniformity, so that the medicament can be released in a sustained way or the problem about end-release is solved; the medicament carrier has low mucous membrane irritation and high biocompatibility; and the medicament safety problems such as medicament burst release and dose pour release are not easily caused.